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Rui-Qun Qi1,12, Li He2,12, Song Zheng1, Yuxiao Hong1, Lei Ma1, Shifa Zhang3, Liping Zhao3, Xinjian Guo4,
Yong Wang5, Jiang-yun Yu6, Lan Fu6, Wei Zhang2, Tingfeng Long2, Chao Zhang1, Guohong Chen1,
Junping Lin1, Chengliang Wang7, Li Zhou8, Qingsheng Mi8, Matthew Weiland8, John Z.S. Chen9, S.S. Salum
Mchenga10, Ya-Kun Wang1, Uwesu Mchepange11, Zhimin Wang1, Hong-Duo Chen1 and Xing-Hua Gao1
Frequent somatic mutations of BRAF (v-raf murine sarcoma viral oncogene homolog B) exon T1799A, which
are implicated in the initial events of promutagenic cellular proliferation, are detected in both malignant
melanomas (MM) and melanocytic nevi (MN). Most of the data regarding BRAF exon T1799A mutation have
been from Caucasian cohorts, and a comprehensive screening of a homogeneous population is lacking. A total of
379 cases of MN and 195 cases of MM were collected from Chinese Han living in three geographical regions in
China, i.e., northeast, southwest, and northwest China. BRAF exon T1799A mutation was detected by PCR and
sequencing from microdissected tumors. In all, 59.8% cases of MN harbored BRAF exon T1799A mutation. Samples
from regions with high UV exposure had higher detection rates than regions with lower UV exposure (73.5, 67.0,
and 38.9%, respectively; w2¼ 31.674, P¼ 1.59E–7). There were no differences in mutation rates between congenital
and acquired MN; however, acquired MN with advanced age of onset had a higher mutation rate than those with
younger age of onset (w2¼ 13.23, P¼ 0.02). In all, 15.0% cases of MM harbored the BRAF mutation. The mutation rate
in MM was not affected by region, histological type, gender, pattern of UV exposure, and age. The study suggests
that the mutation is not necessarily associated with malignant transformation.
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INTRODUCTION
Malignant melanoma (MM) and melanocytic nevus (MN) are,
respectively, malignant and benign forms of melanocytic
tumors. The incidence of cutaneous MM varies among
different races, with Caucasians having the highest rate,
Asians a moderate rate, and blacks the lowest rate. The
clinical and histological types of MM vary among different
ethnicities, such that Caucasians are often afflicted with
superficial spreading MM and nodular MM (Lang and
MacKie, 2005), whereas Asians present with acral lentiginous
MM (Sasaki et al., 2004). Cutaneous MN occurs universally,
although more frequently in Caucasians than in dark-skinned
Africans and Asians. The incidence of MN is also related to
age; there are few cases in early childhood, but the incidence
peaks in the third decade of life and then declines again with
advancing age (Green and Swerdlow, 1989).
BRAF (v-raf murine sarcoma viral oncogene homolog B),
a member of the RAF family, is a critical serine/threonine
kinase in the RAS/mitogen-activated protein kinase pathway
(RAS-RAF-MEK-ERK-MAP kinase pathway). Somatic muta-
tions of BRAF, especially T1799A (V600E) in exon 15, have
been found at varying levels in cases of MM (Davies et al.,
2002; Sasaki et al., 2004; Lang and MacKie, 2005; Poynter
et al., 2006; Saldanha et al., 2006; Liu et al., 2007). The
mutant BRAF promotes melanoma growth and development
and has thus been regarded as one of the key underlying
causes of primary melanomas (Patton et al., 2005; Hoeflich
et al., 2009). Subsequent studies have suggested that the rates
of BRAF mutations are related to the subtypes of MM (Cohen
et al., 2004; Liu et al., 2007; Wu et al., 2007). In addition, there
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is accumulating evidence that MN harbor BRAF T1799A
mutations, with frequencies reaching as high as 80% (Pollock
et al., 2003; Poynter et al., 2006). Transformation of a MN to
MM is not uncommon, but the relatively high detection rate of
BRAF mutation in MN hardly accounts for all the transforma-
tions to MM, thus leaving doubt as to the role of BRAFmutation
in melanoma development (Wu et al., 2007). A recent finding
that BRAF T1799A mutation alone led to long-term melano-
cytic hyperplasia in mice favored the hypothesis that BRAF
mutation is one of the early events leading to melanocytic
proliferation in MN and MM (Dankort et al., 2009).
From the clinical perspective, sunlight exposure, espe-
cially UV light, is generally regarded as one of the important
factors associated with some types of MM and MN (Pollock
et al., 2003). Several studies showed that intermittent UV
exposure correlated with BRAF mutations in MM and MN in
fair-skinned people of various ethnicities (Sasaki et al., 2004;
Liu et al., 2007; Akslen et al., 2008). The importance of
UV exposure to the occurrence of MM or MN is possibly
influenced by skin type and color. Therefore, we undertook a
retrospective study on BRAF mutations in the MN and MM of
Chinese Han, a genetically homogeneous population with
skin types III and IV. The samples were collected from three
regions with distinct geographical conditions.
RESULTS
MN and MM in Chinese Han rarely harbored mutations in BRAF
exon 11 and NRAS exons 2 and 3
Our first-phase study was performed on 280 consecutive
samples of MM (N¼109) and MN (N¼ 171) that yielded
qualified DNA. Sources of the samples and demographic
features of this cohort were similar to those of the larger
cohort, as shown in Tables 1 and 5. No mutations in BRAF
exon 11 were detected in 276 samples (excluding 4 samples
where PCR failed). No mutations in NRAS (neuroblastoma rat
sarcoma oncogene) exon 2 were detected in 267 samples
(PCR failed in 13 samples). Four mutations in NRAS exon 3
were detected in 274 samples (PCR failed in 6 samples). The
mutation at BRAF exon 15 T1799A was detected in 63.7%
(107 of 168) of MN cases and 14.7% (16 of 109) of MM
cases. In addition, one case of BRAF exon 15 A1781G and
one case of G1800A were detected (Table 2). The repre-
sentative figures are shown in Figure 1. Based on this first-
phase study, we discontinued investigating the BRAF exon 11
and NRAS exon 2 and 3 mutations and concentrated on
detection of the BRAF exon 15 T1799A mutation in expanded
sample groups of patients with MN and MM, as described
below.
Chinese Han individuals with MN harbor a high frequency
of BRAF exon 15 T1799A mutation, although geographical
variation exists
Owing to failures in either DNA extraction or PCR, we had
341 cases (out of 379) of MN that qualified for analysis, as
shown in Table 1. We detected the BRAF T1799A mutation in
204 cases (59.8%) of MN in the overall cohort. We also
detected a statistically significant difference in the mutation
rate among the three geographical regions (w2¼31.67,
P¼1.59E–7). By multiple logistic regression analysis, the
mutation rate was significantly lower in MN from northeast
China than those from northwest China (38.9 vs. 67.0%, odds
ratio (OR)¼3.88, 95% confidence interval (CI)¼ 2.17–6.92,
P¼4.76E–6) and southwest China (38.9 vs. 73.5%, OR¼
4.67, 95% CI¼ 2.56–8.51, P¼4.89E–7). There was no
statistical difference in the mutation rates between MN from
patients living in northwest China and southwest China
(w2¼1.14, P¼0.284). With regard to histological types of
MN, there were statistically significant differences in muta-
tion rates among intradermal (173 of 272, 63.6%), compound
(21 of 41, 51.2%), and junctional (10 of 28, 35.7%) MN
(w2¼9.65, P¼8.02E–3).
As shown in Table 3, the mutation rate in congenital MN
(N¼104) was similar to that of acquired MN (N¼152; 58.7
vs. 59.2%) in the overall cohort and in the three geographic
regions (w2 test, all P40.05). A statistically significant
difference in mutation rates was seen in congenital
MN among the three regions (w2¼10.38, P¼5.58E–3). By
multiple logistic regression analysis, the mutation rate was
significantly lower in those with congenital MN from
northeast China than in those from northwest (OR¼2.81,
95% CI¼1.08–7.29, P¼0.034) and southwest China
(OR¼4.83, 95% CI¼1.70–13.76, P¼ 3.18E–3). Similarly,
there was a statistically significant difference in mutation rate
in acquired MN among the three regions (w2¼19.21,
P¼6.73E–5). The rate was significantly lower in acquired
MN from northeast China than in that from northwest
(OR¼4.33, 95% CI¼1.76–10.68, P¼1.44E–3) and south-
west China (OR¼ 6.71, 95% CI¼2.72–16.58, P¼ 3.66E–5).
Two groups of patients with MN sought biopsy or removal
of their lesions. One group of patients (N¼108) had early
warning signs of MM, including itching, pain, broken skin, an
increase in nevus size, changes in coloration, and appear-
ance of new lesions (Friedman et al., 1985). The other group
(N¼159), in whom there were no early warning signs,
sought to remove the MN for cosmetic reasons or out of fear
of potential melanoma development. The mutation rate in
patients with and without early signs was 56.5% (61 of 108
cases) and 59.7% (95 of 159 cases), respectively, which was
not statistically different (w2¼0.28, P¼ 0.59). Although no
unambiguous MM was defined in this cohort of samples,
seven patients with warning signs had intradermal nevus with
mild dysplastic hyperplasia. Four of these cases harbored the
BRAF mutation.
A statistically significant difference in mutation rates was
found among the decadal ages of onset in patients with
acquired MN (w2¼13.23, P¼0.021). Interestingly, the
mutation rate in patients with acquired MN peaked during
the third decade of life (27 of 38, 71.1%), an observation that
is in accordance with the incidence peak of MN in the
general population.
Effect of UV radiation on BRAF mutation in MN of Chinese Han
People with MN living in regions with high UV intensity had
much higher mutation rates than those living in low-intensity
regions. To determine whether UV exposure has a cumula-
tive effect on the BRAF mutation, we investigated the
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Table 1. BRAF exon 15 T1799A mutation in the MN of Chinese Han
Northeast China Northwest China Southwest China
E: 1231240 E: 1011450 E: 1021410
N: 411450 N: 361380 N: 251010
A: 45m A: 2,295m A: 1,896m
UVR: 0.079 Jm2 UVR: 0.164 Jm2 UVR: 0.174 Jm2 Total no.
Selected variable1 Total no.
No. with
mutation (%) Total no.
No. with
mutation (%) Total no.
No. with
mutation (%) Total no.
No. with
mutation (%)
Total no. 113 44 (38.9) 115 77 (67.0) 113 83 (73.5) 341 204 (59.8)
Gender
Male 43 15 (34.9) 55 33 (60.0) 36 26 (72.2) 134 74 (55.2)
Female 70 29 (41.4) 60 44 (73.3) 77 57 (74.0) 207 130 (62.8)
Duration of disease (years)
p10 41 11 (26.8) 36 23 (63.9) 45 34 (75.6) 122 68 (55.7)
11–20 19 6 (31.6) 11 7 (63.6) 19 14 (73.7) 49 27 (55.1)
21–30 14 5 (35.7) 13 9 (69.2) 9 6 (66.7) 36 20 (55.6)
31–40 8 7 (87.5) 10 8 (80.0) 7 7 (100) 25 22 (88.0)
X41 6 3 (50.0) 7 4 (57.1) 4 3 (75.0) 17 10 (58.8)
Age of onset (years)
At birth 42 17 (40.5) 32 21 (65.6) 30 23 (76.7) 104 61 (58.7)
0.1–10 7 2 (28.6) 5 3 (60.0) 7 4 (57.1) 19 9 (47.4)
11–20 8 4 (50.0) 9 5 (55.6) 14 11 (78.6) 31 20 (64.5)
21–30 7 1 (14.3) 14 12 (85.7) 17 14 (82.4) 38 27 (71.1)
31–40 12 5 (41.7) 8 7 (87.5) 10 9 (90.0) 30 21 (70.0)
X41 12 3 (25) 9 3 (33.3) 6 3 (50.0) 27 9 (33.3)
Anatomic site
Constantly exposed 55 20 (36.4) 62 39 (62.9) 69 50 (72.5) 186 109 (58.6)
Intermittently exposed 39 19 (48.7) 36 30 (83.3) 32 28 (87.5) 107 77 (72.0)
Nonexposed 19 5 (26.3) 17 8 (47.1) 12 5 (41.7) 48 18 (37.5)
Danger signs
Yes 33 12 (36.4) 36 23 (63.9) 39 26 (66.7) 108 61 (56.5)
No 70 28 (40.0) 46 30 (65.2) 43 37 (86.0) 159 95 (59.7)
Histogenetic type
IN 89 38 (42.7) 86 63 (73.3) 97 72 (74.2) 272 173 (63.6)
JN 13 3 (23.1) 10 5 (50.0) 5 2 (40.0) 28 10 (35.7)
CN 11 3 (27.3) 19 9 (47.4) 11 9 (81.8) 41 21 (51.2)
Abbreviations: A, altitude; BRAF, v-raf murine sarcoma viral oncogene homolog B; CN, compound nevus; E, east longitude; IN, intradermal nevus; JN,
junctional nevus; MN, melanocytic nevus; N, north latitude.
1The sum of subjects in each subgroup may be less than the total number of subjects because some subjects did not provide the information.
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presence and severity of solar elastosis in the perilesional skin
of MN. We detected recognizable solar elastosis in 23 of 282
MN (8.15%). There was no statistical difference in the
mutation rates between those with solar elastosis and those
without (w2¼0.04, P¼0.84).
Because different anatomical sites receive different levels
of solar exposure, they can be classified into constantly sun-
exposed sites, intermittently exposed sites, and nonexposed
sites (Maldonado et al., 2003). In the overall samples of MN,
there were statistically significant differences in mutation
rates among patients who received different patterns of UV
exposure (w2¼16.63, P¼ 2.45E–4). MN on intermittently
exposed sites had higher mutation rates than those on
constantly sun-exposed sites (w2¼5.23, P¼ 0.022) and
nonexposed sites (w2¼16.59, P¼4.65E–5). As determined
using multiple logistic regression analysis, MN on intermit-
tently exposed sites had a higher rate of BRAF mutation than
those on nonexposed sites (OR¼ 3.31, 95% CI¼ 1.41–7.77,
P¼5.83E–3), whereas there was no statistical difference in
mutation rates between patients with MN on nonexposed
sites and constantly exposed sites (OR¼ 1.67, 95%
CI¼0.76–3.66, P¼0.20).
Acquired MN (N¼152) on intermittently exposed sites
had a statistically significant higher mutation rate than those
Table 2. Description of mutations detected other than BRAF exon 15 T1799A














1.1.1 Male 65 Acquired Yes AL Foot A1781G (D594G) wt
Southwest
China







2.1.1 Female 28 Congenital No IN Lower jaw wt A182G (Q61R)
Northwest
China




LMM Neck wt A182G (Q61R)




2.3.1 Male 14 Acquired Yes IN Labrum T1799A (V600E) C235A (L79I)
Abbreviations: AL, acral lentiginous; BRAF, v-raf murine sarcoma viral oncogene homolog B; CN, compound nevus; F, female; IN, intradermal nevus; JN,
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Figure 1. Representative mutations detected in this study.
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Table 3. BRAF exon 15 T1799A mutation in acquired and congenital melanocytic nevi
Northeast China Northwest China Southwest China Total no.











































Total no. 42 17 (40.5) 47 16 (34.0) 32 21 (65.6) 51 33 (64.7) 30 23 (76.7) 54 41 (75.9) 104 61 (58.7) 152 90 (59.2)
Gender
Male 14 3 (21.4) 16 7 (43.8) 16 10 (62.5) 27 17 (63.0) 9 8 (88.9) 16 13 (81.3) 39 21 (53.8) 59 37 (62.7)
Female 28 14 (50.0) 31 9 (29.0) 16 11 (68.8) 24 16 (66.7) 21 15 (71.4) 38 28 (73.7) 65 40 (61.5) 93 53 (57.0)
Duration of lesions (years)
p10 6 0 35 11 (31.4) 36 23 (63.9) 3 2 (66.7) 42 32 (76.2) 9 2 (22.2) 113 66 (58.4)
11–20 9 2 (22.2) 10 4 (40.0) 5 2 (40.0) 6 5 (83.3) 9 6 (66.7) 10 8 (80.0) 23 10 (43.5) 26 17 (65.4)
21–30 13 5 (38.5) 1 0 10 7 (70.0) 3 2 (66.7) 8 6 (75.0) 1 0 31 18 (58.1) 5 2 (40.0)
31–40 8 7 (87.5) 10 8 (80.0) 6 6 (100) 1 1 (100) 24 21 (87.5) 1 1 (100)
X41 6 3 (50.0) 7 4 (57.1) 4 3 (75.0) 17 10 (58.8)
Age of onset (years)
At birth 42 17 (40.5) 32 21 (65.6) 30 23 (76.7) 104 61 (58.7)
p10 7 2 (28.6) 5 3 (60.0) 7 4 (57.1) 19 9 (47.4)
11–20 8 4 (50.0) 9 5 (55.6) 14 11 (78.6) 31 20 (64.5)
21–30 7 1 (14.3) 14 12 (85.7) 17 14 (82.4) 38 27 (71.1)
31–40 12 5 (41.7) 7 6 (85.7) 10 9 (90.0) 30 21 (70.0)




22 8 (36.4) 22 7 (31.8) 17 9 (52.9) 24 15 (62.5) 20 17 (85.0) 28 20 (71.4) 59 34 (57.6) 74 42 (56.8)
Intermittently
exposed
14 6 (42.9) 15 7 (46.7) 12 10 (83.3) 17 14 (82.4) 7 6 (85.7) 19 16 (84.2) 33 22 (66.7) 51 37 (72.5)
Nonexposed 6 3 (50.0) 10 2 (20.0) 3 2 (66.7) 10 4 (40.0) 3 0 7 5 (71.4) 12 5 (41.7) 27 11 (40.7)
Warning signs
Yes 12 5 (41.7) 17 6 (35.3) 11 7 (63.6) 19 10 (52.6) 10 7 (70.0) 20 16 (80.0) 33 19 (57.6) 56 32 (57.1)
No 27 12 (44.4) 29 10 (34.5) 16 10 (62.5) 22 15 (68.2) 11 9 (81.8) 24 20 (83.3) 54 31 (57.4) 75 45 (60.0)
Solar elastosis
No 39 14 (35.9) 42 15 (35.7) 19 13 (68.4) 29 20 (69.0) 22 17 (77.3) 38 29 (76.3) 80 44 (55.0) 109 64 (58.7)
Yes 1 1 (100) 3 1 (33.3) 1 0 4 1 (25.0) 2 2 (100) 9 7 (77.8) 4 3 (75.0) 16 9 (56.3)
Histogenetic type
IN 34 16 (47.1) 39 13 (33.3) 23 16 (69.6) 37 27 (73.0) 24 18 (75.0) 46 35 (76.1) 81 50 (61.7) 122 75 (61.5)
JN 4 1 (25.0) 5 1 (20.0) 5 3 (60.0) 3 1 (33.3) 1 0 4 2 (50.0) 10 4 (40.0) 12 4 (33.3)
CN 4 0 3 2 (66.7) 4 2 (50.0) 11 5 (45.5) 5 5 (100) 4 4 (100) 13 7 (53.8) 18 11 (61.1)
Abbreviations: BRAF, v-raf murine sarcoma viral oncogene homolog B; CN, compound nevus; IN, intradermal nevus; JN, junctional nevus.
1The sum of subjects in each subgroup may be less than the total number of subjects because some subjects did not provide the information.
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on constantly exposed and nonexposed sites (w2¼7.76,
P¼0.02). MN on intermittently exposed sites harbored
higher mutation rates than those on nonexposed sites
(OR¼3.58, 95%¼ 1.22–10.50, P¼ 0.019); MN on con-
stantly exposed sites also harbored higher rates of mutation
than those on nonexposed sites, but the difference was not
statistically significant (OR¼1.61, 95% CI¼0.60–4.32,
P¼0.34). Intriguingly, when the cohort of congenital MN
(n¼104) was analyzed, there was no statistical difference
in mutation rates among MN from patients who might have
received different patterns of UV exposure (w2¼2.33,
P¼0.31; Table 3).
Status of BRAF exon 15 T1799A mutation in patients with
multiple biopsied samples
Of the 20 patients who offered two or three MN samples, as
shown in Table 4, 75% (15 of 20 patients) had the same BRAF
status in all biopsies. Five patients (25%) had both wild and
mutant types of the BRAF mutation. It seemed that patients
with multiple nevi were inclined to have either the wild type
or the mutant type of BRAF mutation, underlining a
constitutional predilection in the occurrence of BRAF
mutation.
Chinese Han MMs harbored a low frequency of BRAF T1799A
mutation
Of the 195 cases of MM, 180 yielded DNA product for
analysis, as shown in Table 5. Of 180 MMs, 27 (15.0%)
contained the BRAF mutation. No statistically significant
difference in mutation rate was seen between MMs from
northeast China (13.3%) and those from northwest China
(16.9%; w2¼ 0.48, P¼ 0.79). The mutation rates were not
affected by gender, age of onset, pattern of UV exposure,
histological type of MM, or depth of invasive growth as
measured by Breslow thickness (w2 test, all P40.05).
Thirty-six patients with MM reported a preexisting MN.
Five of these (13.9%) had a BRAF mutation. There was no
significant difference in mutation rate between MMs with
preexisting MN and those without MN (w2¼ 0.03, P¼0.86).
Six cases reported a previous history of trauma before the
onset of MM, and none of these harbored the mutation.
DISCUSSION
Ever since the BRAF T1799A mutation was implicated in
MM (Davies et al., 2002), reports of variation in mutation
rates (20–80%) have accumulated in the literature (Davies
et al., 2002; Lang and MacKie, 2005; Akslen et al., 2008).
















Northeast China 1.1 Female 22 Congenital No IN Scalp–nasolabial fold wt–M wt
1.2 Female 30 Uncertain No IN Abdomen–nasolabial fold–lip M–M–M wt
1.3 Female 66 Acquired Yes IN Back–protothorax wt–M wt
1.4 Female 19 Acquired No IN Waist–back M–M wt
1.5 Female 28 Acquired No IN Face–lower jaw–nostril wt–M–M wt
1.6 Female 23 Congenital No IN Face–arm wt–wt wt
1.7 Female 31 Acquired Yes JN Abdomen–buttocks wt–wt wt
1.8 Female 16 Uncertain Uncertain CN–IN Foot–thigh M–M wt
1.9 Female 27 Acquired No CN–IN Interdigit–dorsum manus wt–wt wt
Northwest China 2.1 Male 47 Acquired No IN Occiput–occiput wt–wt wt
2.2 Male 70 Acquired No–yes IN–CN Shoulder–neck M–wt wt
2.3 Female 46 Acquired Yes–no IN Nasal ala–preauricula wt–wt wt
Southwest China 3.1 Female 23 Uncertain Uncertain IN Umbilicus–arm M–M wt
3.2 Female 32 Acquired Yes JN Finger pulp–planta pedis M–M wt
3.3 Female 32 Acquired No IN Post aurem–abdomen 1,2 M–M–M wt
3.4 Female 46 Acquired Uncertain IN Forehead–waist M–wt wt
3.5 Female 30 Acquired Yes IN Neck–waist–abdomen M–M–M wt
3.6 Female 29 Congenital No–Yes IN Foot–leg wt–wt wt
3.7 Female 40 Acquired No IN Face–neck M–M wt
3.8 Male 34 Acquired Yes IN–CN Protothorax–axilla wt–wt wt
Abbreviations: BRAF, v-raf murine sarcoma viral oncogene homolog B; CN, compound nevus; IN, intradermal nevus; JN, junctional nevus; M, mutant type;
MN, melanocytic nevus; NRAS, neuroblastoma rat sarcoma oncogene; wt, wild type.
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Detection of the BRAF T1799A mutation in the MN, albeit in
varying mutation rates, challenged the role of the BRAF
mutation in the ontogenesis of MM. The varying detection
rate of the BRAF T1799A mutation in MM and MN has been
attributed to a variety of parameters, e.g., sample size,
histological type, pattern of UV exposure, stage of progres-
sion, anatomic site of the lesion, and the particular
techniques used (Shinozaki et al., 2004; Liu et al., 2007;
Wu et al., 2007; Besaratinia and Pfeifer, 2008). However,
most of the studies were conducted on samples from
Table 5. BRAF exon 15 T1799A mutation in the MM of Chinese Han
Northeast China Northwest China Southwest China Total no.
Selected variable1 Total no.
No. with
mutation (%) Total no.
No. with
mutation (%) Total no.
No. with
mutation (%) Total no.
No. with
mutation (%)
Total no. 83 11 (13.3) 89 15 (16.9) 8 1 (12.5) 180 27 (15.0)
Gender
Male 45 8 (17.8) 54 9 (16.7) 4 0 103 17 (16.5)
Female 38 3 (7.9) 35 6 (17.1) 4 1 (25.0) 77 10 (13.0)
Age of onset (years)
p30 1 0 3 0 4 0
31–40 5 1 (20.0) 4 1 (25.0) 9 2 (22.2)
41–50 13 2 (15.4) 8 2 (25.0) 1 0 22 4 (18.2)
51–60 13 3 (23.1) 5 0 18 3 (16.7)
61–70 15 1 (6.7) 20 5 (25.0) 3 0 38 6 (15.8)
X70 11 1 (9.1) 10 0 1 0 22 1 (4.5)
Anatomic site
Constantly exposed 16 1 (6.3) 22 5 (22.7) 4 1 (25.0) 42 7 (16.7)
Intermittently exposed 8 1 (12.5) 10 2 (20.0) 0 0 18 3 (16.7)
Nonexposed 59 9 (15.3) 57 8 (14.0) 4 0 120 17 (14.2)
Preexisting nevus
Yes 18 2 (11.1) 14 2 (14.3) 4 1 (25.0) 36 5 (13.9)
No 42 6 (14.3) 42 7 (16.7) 2 0 86 13 (15.1)
Solar elastosis
No 52 6 (11.5) 48 9 (18.8) 4 0 104 15 (14.4)
Yes 4 0 2 1 (50) 1 0 7 1 (14.3)
Histogenetic type
AL 62 9 (14.5) 60 11 (18.3) 5 0 127 20 (15.7)
SSM 9 2 (22.2) 6 2 (33.3) 2 0 17 4 (23.5)
LMM 3 0 3 1 (33.3) 0 0 6 1 (16.7)
NM 7 0 5 1 (20.0) 1 1 (100) 13 2 (15.4)
Melanoma
Melanoma in situ 15 3 (20.0) 8 1 (12.5) 0 0 23 4 (17.4)
Invasive melanoma 68 8 (11.8) 81 14 (17.3) 8 1 (12.5) 157 23 (14.6)
Abbreviations: AL, acral lentiginous melanoma; BRAF, v-raf murine sarcoma viral oncogene homolog B; LMM, lentigo maligna melanoma; MM, malignant
melanoma; NM, nodular melanoma; SSM, superficial spreading melanoma.
1The sum of subjects in each subgroup may be less than the total number of subjects because some subjects did not provide the information.
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light-skinned populations; very few data are available from
Asian populations (Takata and Saida, 2006). The present study
enrolled what is so far the largest cohort of Chinese Han
patients with MM and MN from regions representing different
geographical conditions, thus providing a more comprehen-
sive analysis for factors that might correlate with the BRAF
T1799A mutation. All the patients were of Chinese Han
ethnicity and had skin types III and IV, ensuring a relatively
homogeneous genetic background. A major drawback of the
study was that we were unable to collect a sufficient number
of MM samples from southwest China because of adminis-
trative restrictions.
Functional mutations in the RAS/mitogen-activated protein
kinase pathway may lead to cell proliferation (Fecher et al.,
2008). Mutations in NRAS exons 2 and 3, BRAF exon 11,
and, most prevalently, BRAF exon 15 T1799A have been
reported in MN and MM (Poynter et al., 2006; Saldanha
et al., 2006). In our first-phase study, we did not find
mutations in BRAF exon 11 and NRAS exon 2 in a total of
280 cases of MN and MM from Chinese Han. We detected
only 4 cases (out of 274 samples) with a mutation in NRAS
exon 3. This is strikingly different from the reported data on
MN and MMs from fair-skinned people (Papp et al., 2005;
Bauer et al., 2007; Akslen et al., 2008).
The overall BRAF T1799A mutation rate in Chinese MN
was 59.8%, comparable to that in populations of other
ethnicities (Pollock et al., 2003; Poynter et al., 2006).
However, we noticed a very significant difference in mutation
rates among the different Chinese regions. The three geo-
graphic regions that we studied have different altitudes,
latitudes, and intensities of annual solar radiance (Gong
et al., 1992). In our study, we found that acquired MN from
regions with higher UV intensity harbored higher mutation
rates in BRAF exon 15 T1799A. An interesting finding was that
the same trend was observed for congenital MN, the
occurrence of which should not be affected by solar exposure.
We postulate that either there are different pathogenesis
pathways in congenital and acquired MN or that UV exposure
has an indirect role in promoting the BRAF mutation.
Several studies have reported frequent BRAF mutations in
congenital MN (Papp et al., 2005; Wu et al., 2007). Others
have reported that congenital MN harbor a low rate of BRAF
mutations but a high rate of NRAS mutations (Bauer et al.,
2007; Dessars et al., 2009). We found that 58.7% of
congenital MN harbored a BRAF mutation, whereas few
samples harbored the NRAS mutation. Furthermore, the rate
of BRAF mutation in congenital MN was influenced only by
regional variation and not by the other documented variables
such as age, gender, duration of the disease, or pattern of
solar exposure. The underlying causes of the BRAF mutation
in congenital MN from Chinese Han remain elusive.
Solar exposure is the most common factor in acquired MN
development. Studies have shown that ambient UV exposure
at early stages of life contributes to the BRAFmutation in MN,
especially when patients are intermittently exposed to solar
radiation (Thomas et al., 2007). Scoring of solar elastosis was
considered a reliable histological method in recording the
accumulated effect of UV exposure (Maldonado et al., 2003;
Landi et al., 2006). For Chinese Han patients with skin type III
or IV, only a minor portion of samples showed recognizable
signs of solar elastosis. Patients with acquired MN on sites that
might receive intermittent ambient UV exposure harbored
a higher rate of BRAFmutations than those on nonexposed and
constantly exposed sites. The BRAF mutation might account
for the occurrence of a proportion of acquired MN, although
there may be other elusive determinants.
In this study, MN with previous warning signs harbored
mutation rates similar to those for whom there were no such
signs, suggesting that the perturbed clinical course in MN did
not contribute to BRAF mutation. In the MM cohort, there
were 36 patients with a previous history of de novo MN.
The mutation rate was 13.9%, comparable to that in patients
with primary MM. Taken together, we speculate that the
BRAF T1799A mutation is an initial event in melanocytic
hyperplasia but not a decisive event in melanocyte carcino-
genesis (Pollock et al., 2003).
Multiple nevi from the same patient tended to have a
concurrent state of BRAF mutation (Table 4). Similar findings
were reported by Kumar et al. (2004). The findings indicated
that a genetic predisposition for the somatic BRAF mutation
exists in MN. Germline mutation was not detected inB4,000
individuals (MM patients and controls) in a single study
(James et al., 2006) nor in 80 independent melanoma-prone
families or patients with multiple primary melanoma without
a familial history (Laud et al., 2003).
MM is relatively rare in Chinese Han. Among the four
major histological types of MM, acral lentiginous melanoma is
the most prevalent (Sun et al., 2003). The BRAF mutation was
detected in 15% of Chinese Han patients with MM, a
moderate mutation rate similar to that observed in Japanese
studies. Most of the MM samples were collected from
northeast China and northwest China (171 cases). Although
the geographical conditions were quite distinct between these
two regions, we found no difference in mutation rate between
the two groups. Furthermore, the mutation rate in samples
from these two regions was not affected by any of the
categorical variables listed in Table 3. Our results suggest that
BRAF mutations (as well as NRAS mutations) have a smaller
role in the carcinogenesis of MM in Chinese Han than in
Western patients and that other genetic abnormalities might be
involved in the development of MM (Landi et al., 2006;
Dankort et al., 2009; Yu et al., 2009). It seems that there is a
higher penetrance of BRAF mutations in the progression from
MN to MM in Caucasians versus Chinese Han. The possible
existence of polymorphisms in modifier genes may account for
these findings, as suggested in two recent studies (Demenais
et al., 2010; Dworkin et al., 2010). However, this issue has not
yet been addressed in the MMs of Chinese Han.
MATERIALS AND METHODS
Sources of samples
Formalin-fixed paraffin-embedded tissue blocks histologically diag-
nosed as MN and MM were retrieved from several reference
hospitals located in northeast China, northwest China, and southwest
China. The geographical conditions are described in Table 1 (Gong
et al., 1992). In total, we collected 379 cases of MN and 195 cases of
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MM. In addition, we collected 20 cases in which more than two
biopsied MN samples from different anatomic locations were
collected (Table 4). Congenital nevi were defined as nevi that are
present at birth (Bauer et al., 2007). All samples were from local
inhabitants of Chinese Han. Available demographic information was
recorded from medical records. Patient consent for experiments was
not required because patients consented to the storage and use of their
tissue left over from surgery at the disposal of the hospitals; research
use of such samples is lawful in China. The study was approved by the
institutional review board of China Medical University and was in
accordance with the Declaration of Helsinki Principles.
Histological evaluation of UV exposure
As described, representative areas of solar elastosis on hematoxylin
and eosin–stained sections of normal skin surrounding the MN and
MM were examined (Maldonado et al., 2003; Landi et al., 2006).
Dichotomous categorization of the presence or absence of solar
elastosis was used for grading.
Laser capture microdissection and DNA extraction
Five to 10 consecutive 8 mm-thick sections were cut and stained with
hematoxylin. Using a laser capture microdissection system (MMI,
Glattbrugg, Switzerland), nevus and melanoma cells were micro-
dissected and collected. DNA was extracted using the QIAGEN
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions.
PCR and allele-specific PCR
PCR and allele-specific PCR were carried out with the GeneAmp
PCR System 9700 (PerkinElmer, Oak Brook, IL). The PCR conditions
employed were as previously described (Davies et al., 2002; Lang
and MacKie, 2005).
Sequencing
All sequencing was performed on an ABI 3730xl sequencer (Applied
Biosystems, Foster City, CA). Mutations were detected using Chromas
2.31, Technelysium Pty, Queensland, Australia. All chromatograms
were also manually reviewed to confirm the mutations.
Statistical analysis
All data were entered into SPSS (version 15.0, SPSS, Chicago, IL) for
statistical analysis. Categorical data were analyzed using the w2 test
or Fisher’s exact test. Multivariable logistic regression analyses were
performed to obtain the OR and 95% CI. For each selected variable
of interest, variables such as region, gender, age of diagnosis, histo-
logical type, or UV exposure pattern were included for adjustment
whenever appropriate. Owing to the small number of MM cases
(eight) from southwest China, the statistical analyses on MM were
performed mainly on cohorts from northeast and northwest China.
A two-tailed Po0.05 was considered statistically significant.
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